metricas
covid
Clinics A phase III, randomized, non-inferiority study comparing the efficacy and safety...
Journal Information

Statistics

Follow this link to access the full text of the article

CLINICAL SCIENCE
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
Roberto HeggI,
Corresponding author
robertohegg@gmail.com

Corresponding author
, André MattarI, João Nunes de Matos NetoII, José Luiz PedriniIII, Sabina Bandeira AleixoIV, Roberto Odebrecht RochaV, Renato Peixoto Cramer JuniorVI, Sylvie van-Eyll-RochaVII
I Hospital Pérola Byington, Centro de Referência da Saúde da Mulher, São Paulo/SP, Brazil
II Hospital Universitário de Brasília, Brasília/DF, Brazil
III Hospital Nossa Senhora da Conceição, Porto Alegre/RS, Brazil
IV Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim/ES, Brazil
V Hospital Santa Marcelina, São Paulo/SP, Brazil
VI Hospital Bruno Born, Lajeado/RS, Brazil
VII Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo/SP, Brazil
Read
1519
Times
was read the article
596
Total PDF
923
Total HTML
Share statistics
Article information
ISSN: 18075932
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 55 41 96
2025 11 222 190 412
2025 10 78 38 116
2025 9 62 25 87
2025 8 63 16 79
2025 7 81 20 101
2025 6 25 3 28
2025 5 25 7 32
2025 4 22 2 24
2025 3 16 7 23
2025 2 13 4 17
2025 1 14 7 21
2024 12 13 1 14
2024 11 20 11 31
2024 10 17 20 37
2024 9 24 10 34
2024 8 20 13 33
2024 7 22 24 46
2024 6 13 7 20
2024 5 13 9 22
2024 4 14 8 22
2024 3 12 10 22
2024 2 10 8 18
2024 1 9 11 20
2023 12 6 20 26
2023 11 11 17 28
2023 10 8 20 28
2023 9 7 13 20
2023 8 1 7 8
2023 7 4 9 13
2023 6 5 3 8
2023 5 2 0 2
2023 4 5 4 9
2023 3 4 1 5
2023 2 2 0 2
2023 1 0 6 6
2022 12 4 4 8
2022 11 1 0 1
Show all

Follow this link to access the full text of the article